<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NITROMIST- nitroglycerin aerosol, spray </strong><br>NovaDel Pharma Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">NitroMist™ is a nitrate vasodilator indicated
                                    for acute relief of an attack or acute prophylaxis of angina
                                    pectoris due to <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (<a href="#A56CAC08-DC44-4968-AC61-FF786DB79332">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>At the onset of an attack, one or two metered sprays
                                        should be administered on or under the tongue. A spray may
                                        be repeated approximately every 5 minutes as needed
                                            (<a href="#BD068A8B-2508-4C56-A471-43DD8966430B">2.1</a>). </li>
<li>Maximum of 3 metered sprays are recommended within a
                                        15-minute period. If <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> persists after a total of 3   sprays, prompt medical attention is recommended (<a href="#BD068A8B-2508-4C56-A471-43DD8966430B">2.1</a>).</li>
<li>May be used prophylactically 5 to 10 minutes before
                                        engaging in activities that might precipitate an acute
                                        attack (<a href="#BD068A8B-2508-4C56-A471-43DD8966430B">2.1</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Lingual aerosol, 400 mcg per spray, 230 metered sprays
                                    per container (<a href="#DC2EAC60-C938-46C9-8F39-2A8B855E7FD1">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Use of a selective inhibitor of cyclic guanosine
                                        monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5
                                        inhibitors), such as sildenafil, vardenafil, and tadalafil
                                            (<a href="#D526D83D-446D-49B7-8E63-517025F99FE1">4.1</a>) </li>
<li>Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (<a href="#CAED389E-EFE2-4CAD-8AF8-E828542442BF">4.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span> (<a href="#C9B0B196-DDC0-4486-82E4-4600B066C453">4.3</a>)</li>
<li>History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to NitroMist or to other
                                        nitrates or nitrites (<a href="#D3D0640C-6C9F-4141-B7EF-31A619827D43">4.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul><li>Tolerance: Excessive use may lead to tolerance (<a href="#D79AD1CA-87ED-495D-BB7F-15AB8D2B6E45">5.1</a>).</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>,
                                    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (<a href="#A366D750-2C1C-4537-8FB0-70534281FADA">6</a>). </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>PDE5 inhibitors: Concomitant use contraindicated
                                            (<a href="#D526D83D-446D-49B7-8E63-517025F99FE1">4.1</a>, <a href="#AE9F525B-9BFD-479A-AF31-559063B65C27">7.1</a>)</li>
<li>Antihypertensives: Possible additive hypotensive effects
                                            (<a href="#ECF825CD-5E5A-4071-B1B1-78A41F81A5C9">7.2</a>)</li>
<li>Aspirin: increased nitroglycerin levels (<a href="#EC0370B4-CB16-40F1-8E70-322AAB35AF9F">7.3</a>)</li>
<li>Tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator (t-PA): decreased
                                        thrombolytic effect (<a href="#F328B3E1-7A47-45ED-9864-78A08F3940E0">7.4</a>)</li>
<li>Heparin: anticoagulant effect of heparin may be reduced.
                                        Monitor APTT. (<a href="#A473B11A-E7D2-4AC0-B92D-D7F1606B647C">7.5</a>)</li>
<li>Ergotamine: increased bioavailability of ergotamine. Avoid
                                        concomitant use. (<a href="#B5FFE3B9-6254-4CFB-A285-DFF4F74A7BFD">7.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 3/2007</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1 Recommended Dosage</a></h2>
<h2><a href="#section-3.2" class="toc">2.2 Priming the Container</a></h2>
<h2><a href="#section-3.3" class="toc">2.3 Administration</a></h2>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-5.1" class="toc">4.1 PDE5 inhibitor use</a></h2>
<h2><a href="#section-5.2" class="toc">4.2 Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">4.3 <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span></a></h2>
<h2><a href="#section-5.4" class="toc">4.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></a></h2>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1 Tolerance</a></h2>
<h2><a href="#section-6.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-6.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">Hypertrophic Cardiomyopathy</span></a></h2>
<h2><a href="#section-6.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h2><a href="#section-7.2" class="toc">6.2 <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></a></h2>
<h2><a href="#section-7.3" class="toc">6.3 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-7.4" class="toc">6.4 <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-8.1" class="toc">7.1 PDE5 inhibitors</a></h2>
<h2><a href="#section-8.2" class="toc">7.2 Antihypertensives</a></h2>
<h2><a href="#section-8.3" class="toc">7.3 Aspirin</a></h2>
<h2><a href="#section-8.4" class="toc">7.4 Tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">Plasminogen</span> Activator (t-PA)</a></h2>
<h2><a href="#section-8.5" class="toc">7.5 Heparin</a></h2>
<h2><a href="#section-8.6" class="toc">7.6 Ergotamine</a></h2>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-9.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1 Interaction with PDE5 inhibitors</a></h2>
<h2><a href="#section-16.2" class="toc">17.2 Administration</a></h2>
<h2><a href="#section-16.3" class="toc">17.3 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></a></h2>
<h2><a href="#section-16.5" class="toc">17.5 Container information</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="A56CAC08-DC44-4968-AC61-FF786DB79332"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">NitroMist is indicated for acute relief of an attack or acute
                            prophylaxis of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> due to coronary artery
                        disease.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="E132D2DC-0D96-46ED-8D68-FF079FB4B390"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="BD068A8B-2508-4C56-A471-43DD8966430B"></a><a name="section-3.1"></a><p></p>
<h2>2.1 Recommended Dosage</h2>
<p class="First">At the onset of an attack, one or two metered sprays
                                    should be administered on or under the tongue. A spray may be
                                    repeated approximately every 5 minutes as needed. No more than 3
                                    metered sprays are recommended within a 15-minute period. If
                                    <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> persists after a total of 3 sprays, prompt medical
                                    attention is recommended. NitroMist may be used prophylactically
                                    5 to 10 minutes before engaging in activities that might
                                    precipitate an acute attack.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A6941BBB-5E28-4C68-9E96-885C4A79EB68"></a><a name="section-3.2"></a><p></p>
<h2>2.2 Priming the Container</h2>
<p class="First">After an initial priming of 10 sprays, each metered spray
                                    of NitroMist delivers 33 mg of solution containing 400 mcg of
                                    nitroglycerin. It will remain adequately primed for 6 weeks. If
                                    the product is not used within 6 weeks, it can be adequately
                                    re-primed with 2 sprays. There are 230 metered sprays per
                                    container, but the total number of available doses depends on
                                    the number of sprays per use (1 or 2 sprays), and the frequency
                                    of priming.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CDAE66DA-88D7-4F93-838F-05ACB6C4905C"></a><a name="section-3.3"></a><p></p>
<h2>2.3 Administration</h2>
<p class="First">During use the patient should rest, ideally in the
                                    sitting position. The container should be held vertically with
                                    the valve head uppermost and the spray orifice as close to the
                                    mouth as possible. The dose should preferably be sprayed into
                                    the mouth on or under the tongue by pressing the button firmly
                                    and the mouth should be closed immediately after each dose. THE
                                    SPRAY SHOULD NOT BE INHALED. Patients should be instructed to
                                    familiarize themselves with the position of the spray orifice,
                                    which can be identified by the finger rest on top of the valve,
                                    in order to facilitate orientation for administration at night.</p>
<ol>
<li>Do not shake container.</li>
<li>Remove plastic cap</li>
<li>Press actuator button 10 times to ensure proper dose
                                        priming (holding unit away from yourself and others).</li>
<li>Hold container upright with forefinger on top of the
                                        actuator button.</li>
<li>Open mouth and bring the container as close as possible.</li>
<li>Press the actuator button firmly with forefinger to
                                        release spray onto or under the tongue.</li>
<li>Release button and close mouth. The medication should not
                                        be spit out or the mouth rinsed for 5 to 10 minutes
                                        following administration.</li>
<li>If a second administration is required to obtain relief,
                                        repeat steps 4, 5, and 6.</li>
<li>Replace plastic cover.</li>
<li>If the product is not used for more than 6 weeks, then it
                                        can be adequately re-primed with 2 sprays.</li>
</ol>
<p>The level of the liquid in the container should be
                                    periodically checked. While the container is in the upright
                                    position, if the liquid reaches the top or middle of the hole on
                                    the side of the container, one should order more. When the
                                    liquid reaches the bottom of the hole, the remaining doses will
                                    have less than label content.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="DC2EAC60-C938-46C9-8F39-2A8B855E7FD1"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Lingual aerosol, 400 mcg per spray, 230 metered sprays per
                            container</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="AA9E0E9D-19EF-4872-830A-6372C5969C7F"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="D526D83D-446D-49B7-8E63-517025F99FE1"></a><a name="section-5.1"></a><p></p>
<h2>4.1 PDE5 inhibitor use</h2>
<p class="First">Administration of NitroMist is contraindicated in
                                    patients who are using a selective inhibitor of cyclic guanosine
                                    monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5),
                                    as PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil
                                    have been shown to potentiate the hypotensive effects of organic
                                    nitrates [see <span class="Bold Italics"><span class="Emphasis"><a href="#AE9F525B-9BFD-479A-AF31-559063B65C27">DRUG INTERACTIONS 7.1</a></span></span><span class="Italics"><span class="Emphasis">)].</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="CAED389E-EFE2-4CAD-8AF8-E828542442BF"></a><a name="section-5.2"></a><p></p>
<h2>4.2 Severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></h2>
<p class="First">NitroMist is contraindicated in patients with severe
                                    <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="C9B0B196-DDC0-4486-82E4-4600B066C453"></a><a name="section-5.3"></a><p></p>
<h2>4.3 <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased intracranial pressure</span></h2>
<p class="First">NitroMist is contraindicated in patients with increased
                                    intracranial pressure</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="D3D0640C-6C9F-4141-B7EF-31A619827D43"></a><a name="section-5.4"></a><p></p>
<h2>4.4 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">NitroMist is contraindicated in patients who have shown
                                    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it or to other nitrates or nitrites. Skin
                                    reactions consistent with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> have been observed
                                    with organic nitrates.</p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="D116AC2A-4896-4428-B202-1368549F0AED"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="D79AD1CA-87ED-495D-BB7F-15AB8D2B6E45"></a><a name="section-6.1"></a><p></p>
<h2>5.1 Tolerance</h2>
<p class="First">Excessive use may lead to the development of tolerance.
                                    Only the smallest number of doses required for effective relief
                                    of the acute <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal attack</span> should be used [see <span class="Bold Italics"><span class="Emphasis"><a href="#E132D2DC-0D96-46ED-8D68-FF079FB4B390">DOSAGE AND ADMINISTRATION (2)</a></span></span>].</p>
<p>As tolerance to other forms of nitroglycerin develops,
                                    the effect of sublingual nitroglycerin on exercise tolerance,
                                    although still observable, is reduced.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="BD81EBCC-EF96-4049-9FCC-FB958C02E5B4"></a><a name="section-6.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">Severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, particularly with upright posture,
                                    may occur even with small doses of nitroglycerin. The drug
                                    should therefore be used with caution in patients who may be
                                    volume-depleted or who, for whatever reason, are already
                                    hypotensive. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> induced by nitroglycerin may be
                                    accompanied by paradoxical <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and increased angina
                                    pectoris.</p>
<p>The benefits of NitroMist in patients with acute
                                    <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> have not been
                                    established. If one elects to use NitroMist in these conditions,
                                    careful clinical or hemodynamic monitoring must be used because
                                    of the possibility of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="D23C9247-3E48-4D23-A6FD-142D0DB27B28"></a><a name="section-6.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">Hypertrophic Cardiomyopathy</span></h2>
<p class="First">Nitrate therapy may aggravate the angina caused by
                                    <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="D5E577C9-57B2-40CA-AF1E-44BA4AC8E6D2"></a><a name="section-6.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First">Nitroglycerin produces dose-related <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, which may
                                    be severe. Tolerance to <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> occurs.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="A366D750-2C1C-4537-8FB0-70534281FADA"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="E8460011-46EB-414F-8525-CA70BCB9EB52"></a><a name="section-7.1"></a><p></p>
<h2>6.1 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, which may be severe and persistent, may occur
                                    immediately after nitroglycerin use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="D7C83A87-F324-48DF-B5F2-FBEFC3B1EFEA"></a><a name="section-7.2"></a><p></p>
<h2>6.2 <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> have been
                                    reported in patients receiving nitrate therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="D8F92E92-1638-495F-93A4-0B0D685F38B0"></a><a name="section-7.3"></a><p></p>
<h2>6.3 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Postural hypotension</span>, as manifest by <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>,
                                    <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, and other symptoms, may develop occasionally,
                                    particularly in erect, immobile patients. Marked sensitivity to
                                    the hypotensive effects of nitrates (manifested by <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>,
                                    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, and collapse) may occur
                                    at therapeutic doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="BEA03097-12F1-400C-8358-63FD4527225A"></a><a name="section-7.4"></a><p></p>
<h2>6.4 <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> due to nitrate <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> has been
                                reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="BC90562A-E3FF-43E1-A014-A276031B68CB"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="AE9F525B-9BFD-479A-AF31-559063B65C27"></a><a name="section-8.1"></a><p></p>
<h2>7.1 PDE5 inhibitors</h2>
<p class="First">Administration of NitroMist is contraindicated in
                                    patients who are using a selective inhibitor of cyclic guanosine
                                    monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5).      PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil
                                    have been shown to potentiate the hypotensive effects of organic
                                    nitrates.</p>
<p>The time course and dose <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> of this interaction
                                    have not been studied, and use within a few days of one another
                                    cannot be recommended. Appropriate supportive care for the
                                    severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has not been studied, but it seems reasonable
                                    to treat this as a nitrate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, with elevation of the
                                    extremities and with central volume expansion. The use of any
                                    form of nitroglycerin during the early days of acute myocardial
                                    <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> requires particular attention to hemodynamic
                                    monitoring and clinical status.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ECF825CD-5E5A-4071-B1B1-78A41F81A5C9"></a><a name="section-8.2"></a><p></p>
<h2>7.2 Antihypertensives</h2>
<p class="First">Patients receiving antihypertensive drugs,
                                    beta-adrenergic blockers, and nitrates should be observed for
                                    possible additive hypotensive effects. Marked orthostatic
                                    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has been reported when calcium channel blockers and
                                    organic nitrates were used concomitantly.</p>
<p>Labetolol blunts the <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">reflex tachycardia</span> produced by
                                    nitroglycerin without preventing its hypotensive effects. If
                                    labetolol is used with nitroglycerin in patients with angina
                                    pectoris, additional hypotensive effects may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="EC0370B4-CB16-40F1-8E70-322AAB35AF9F"></a><a name="section-8.3"></a><p></p>
<h2>7.3 Aspirin</h2>
<p class="First">Coadministration of aspirin and nitroglycerin has been
                                    reported to result in increased nitroglycerin maximum
                                    concentrations by as much as 67% and AUC by 73%
                                    when administered as a single dose. The vasodilatory and
                                    hemodynamic effects of nitroglycerin may be enhanced by
                                    concomitant administration of aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="F328B3E1-7A47-45ED-9864-78A08F3940E0"></a><a name="section-8.4"></a><p></p>
<h2>7.4 Tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">Plasminogen</span> Activator (t-PA)</h2>
<p class="First">Intravenous administration of nitroglycerin decreases the
                                    thrombolytic effect of tissue-type <span class="product-label-link" type="condition" conceptid="4238994" conceptname="Plasminogen assay">plasminogen</span> activator (t-PA).
                                    Plasma levels of t-PA are reduced when coadministered with
                                    nitroglycerin. Therefore, caution should be observed in patients
                                    receiving nitroglycerin during t-PA therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A473B11A-E7D2-4AC0-B92D-D7F1606B647C"></a><a name="section-8.5"></a><p></p>
<h2>7.5 Heparin</h2>
<p class="First">Intravenous nitroglycerin reduces the anticoagulant
                                    effect of heparin. <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">Activated partial thromboplastin times</span> (APTT)
                                    should be monitored in patients receiving heparin and
                                    intravenous nitroglycerin. It is not known if this effect occurs
                                    following single nitroglycerin doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="B5FFE3B9-6254-4CFB-A285-DFF4F74A7BFD"></a><a name="section-8.6"></a><p></p>
<h2>7.6 Ergotamine</h2>
<p class="First">Oral administration of nitroglycerin markedly decreases
                                    the first-pass metabolism of dihydroergotamine and subsequently
                                    increases its oral bioavailability. Ergotamine is known to
                                    precipitate <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>. Therefore, patients receiving
                                    sublingual nitroglycerin should avoid ergotamine and related
                                    drugs or be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span> if this is not
                                    possible.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ACF7C4B6-1784-4AB2-8795-609C9DE0E8F1"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="E259C172-7583-4C87-BD8F-FD81E3B3C301"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy category C: Animal reproduction and
                                    <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies have not been conducted with NitroMist or
                                    nitroglycerin sublingual tablets. It is also not known whether
                                    NitroMist can cause fetal harm when administered to a pregnant
                                    woman or can affect reproduction capacity. A <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>
                                    study was conducted in the third mating of F<span class="Sub">0</span> generation female rats administered dietary nitroglycerin for
                                    gestation days 6 to 15 at dose levels used in the 3-generation
                                    reproduction study. In offspring of the high-dose nitroglycerin
                                    group, increased incidence of <span class="product-label-link" type="condition" conceptid="201061" conceptname="Diaphragmatic hernia">diaphragmatic hernias</span> and
                                    decreased hyoid bone ossification were seen. The latter finding
                                    probably reflects delayed development rather than a potential
                                    teratogenic effect, thus indicating no clear evidence of
                                    <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> of nitroglycerin.</p>
<p>There are no adequate and well controlled studies in
                                    pregnant women. NitroMist should be given to a pregnant woman
                                    only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="CAE7A69E-0A34-4C0E-96EA-B6DDF3410D59"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether nitroglycerin is excreted in
                                    human milk. Because many drugs are excreted in human milk,
                                    caution should be exercised when NitroMist is administered to a
                                    nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="AA837662-0031-40B7-8A36-64BC8BB39E78"></a><a name="section-9.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of nitroglycerin in
                                    pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="E5B76E0E-B0EC-40FB-962D-6FAB2D8B0D89"></a><a name="section-9.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of NitroMist did not include sufficient
                                    numbers of subjects aged 65 and over to determine whether they
                                    respond differently from younger subjects. Other reported
                                    clinical experience has not identified differences in responses
                                    between elderly (≥65 years) and younger (&lt;65
                                    years) patients. In general, dose selection for an elderly
                                    patient should be cautious, usually starting at the low end of
                                    the dosing range, reflecting the greater frequency of decreased
                                    hepatic, renal, or cardiac function, and of concomitant disease
                                    or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="B73AA017-521C-476F-839E-AAC18B5C544B"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="Italics"><span class="Emphasis">Signs and symptoms of hemodynamic                         effects:</span></span> The effects of nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are generally the
                            results of nitroglycerin’s capacity to induce <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>,
                            venous pooling, reduced <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. These
                            hemodynamic changes may have protean manifestations, including increased
                            intracranial pressure with any or all of persistent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">throbbing headache</span>,
                            <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, and moderate <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>; <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>;
                            <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (possibly with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span> and even
                            <span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span>); <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> (especially in the upright posture); <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>,
                            later followed by reduced ventilatory effort, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, with the skin
                            either <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span>; <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>;
                            <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>; <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>; <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>; and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>No specific antagonist to the vasodilator effects of
                            nitroglycerin is known, and no intervention has been subject to
                            controlled study as a therapy of nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. Because the
                            <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> associated with nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is the result of
                            venodilatation and arterial <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>, prudent therapy in this
                            situation should be directed toward increase in central fluid volume.
                            Passive elevation of the patient’s legs may be sufficient, but
                            intravenous infusion of normal saline or similar fluid may also be
                            necessary.</p>
<p>The use of epinephrine or other arterial vasoconstrictors in this
                            setting is not recommended.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>,
                            therapy resulting in central volume expansion is not without hazard.
                            Treatment of nitroglycerin <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in these patients may be subtle and
                            difficult, and invasive monitoring may be required.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span></span></span>: <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">Methemoglobinemia</span> has been rarely reported with organic
                            nitrates. The diagnosis should be suspected in patients who exhibit
                            signs of impaired oxygen delivery despite adequate arterial
                            PO<span class="Sub">2</span>. Classically, methemoglobinemic blood is described as
                            chocolate brown, without color change on exposure to air.</p>
<p>If <span class="product-label-link" type="condition" conceptid="432882" conceptname="Methemoglobinemia">methemoglobinemia</span> is present, intravenous administration of          methylene blue, 1 to 2 mg/kg of body weight, may be
                        required.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="F3C835FA-91C3-4FB4-87D6-312597BEEFA8"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Nitroglycerin, an organic nitrate, is a vasodilator which has
                            effects on both arteries and veins. The chemical name for nitroglycerin
                            is 1,2,3-propanetriol trinitrate
                                (C<span class="Sub">3</span>H<span class="Sub">5</span>N<span class="Sub">3</span>O<span class="Sub">9</span>). The compound
                            has a molecular weight of 227.09. The chemical structure is:</p>
<p><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=F9EB07A2-5EBC-40EA-9890-1A0B03E859FF&amp;name=nitromist-figure-1.jpg"></p>
<p>NitroMist (nitroglycerin) lingual aerosol is a metered-dose spray
                            containing 230 metered sprays of nitroglycerin. This product delivers
                            400 mcg of nitroglycerin per actuation in the form of spray droplets on
                            or under the tongue. Inactive ingredients: caprylic/capric diglycerol
                            succinate, peppermint oil, L(‑)‑menthol,
                        n-butane.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CBE1EEB3-03C0-436C-9F33-054671946A08"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="CF4828E9-1A3A-4AA7-9B08-B598915FADDC"></a><a name="section-12.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Nitroglycerin forms free radical nitric oxide (NO), which
                                    activates guanylate cyclase, resulting in an increase of
                                    guanosine 3’,5’-monophosphate (cyclic GMP)
                                    in smooth muscle and other tissues. This eventually leads to
                                    dephosphorylation of myosin light chains, which regulates the                       contractile state in smooth muscle and results in
                                    <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="A69AC7E3-6148-42C0-B20F-4EB681377C1D"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The principal pharmacological action of nitroglycerin is
                                    relaxation of vascular smooth muscle. Although venous effects
                                    predominate, nitroglycerin produces, in a dose-related manner,
                                    dilation of both arterial and venous beds. Dilation of the
                                    postcapillary vessels, including large veins, promotes
                                    peripheral pooling of blood, decreases venous return to the
                                    heart, and reduces left ventricular end-diastolic pressure
                                    (preload). Nitroglycerin also produces arteriolar relaxation,
                                    thereby reducing peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> and arterial
                                    pressure (after load), and dilates large epicardial coronary
                                    arteries; however, the extent to which this latter effect
                                    contributes to the relief of exertional angina is unclear.</p>
<p>Therapeutic doses of nitroglycerin may reduce systolic,
                                    diastolic and mean arterial blood pressure. Effective coronary
                                    perfusion pressure is usually maintained, but can be compromised
                                    if blood pressure <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> excessively or increased heart rate
                                    decreases diastolic filling time.<br>Elevated central venous
                                    and pulmonary capillary wedge pressures, and pulmonary and
                                    systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> are also reduced by nitroglycerin
                                    therapy. Heart rate is usually slightly increased, presumably a
                                    reflex response to the <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>. <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">Cardiac index</span> may
                                    be increased, decreased, or unchanged. Myocardial oxygen
                                    consumption or demand (as measured by the pressure-rate product,
                                    <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span>-time index, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>-work index) is decreased and a
                                    more favorable supply-demand ratio can be achieved. Patients
                                    with elevated left ventricular filling pressure and increased
                                    systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> in association with a depressed
                                    <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> are likely to experience an improvement in cardiac
                                    index. In contrast, when filling pressures and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> are
                                    normal, <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> may be slightly reduced following
                                    nitroglycerin administration.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="FB8E1F4C-74D2-4AEF-97CB-4208E814256F"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Nitroglycerin is rapidly absorbed following lingual spray
                                    administration. In a pharmacokinetic study when a single 1200
                                    mcg dose (three activations of a 400 mcg dose) of NitroMist was
                                    administered to healthy volunteers (n=12), all subjects had
                                    detectable trinitroglycerin plasma levels (mean C<span class="Sub">max</span>
                                    0.8 ± 0.7 ng/mL and t<span class="Sub">max</span> of 8 minutes, range
                                    4 to 15 minutes) beginning at 2 minutes post-dose and higher
                                    levels of the 1,2- (mean C<span class="Sub">max</span> 3.7 ± 1 ng/mL
                                    and t<span class="Sub">max</span> 34 ± 21 minutes, range 15 to 90
                                    minutes) and 1,3-dinitroglycerin metabolites (mean
                                    C<span class="Sub">max</span> 1 ± 0.3 ng/mL and mean t<span class="Sub">max</span>
                                    41 ± 20 minutes, range 20 to 90 minutes). </p>
<p>The volume of distribution of nitroglycerin following
                                    intravenous administration is 3.3 L/kg. </p>
<p>A liver reductase enzyme is of primary importance in the
                                    metabolism of nitroglycerin to glycerol di- and mononitrate
                                    metabolites and ultimately to glycerol and organic nitrate.
                                    Known sites of extrahepatic metabolism include red blood cells
                                    and vascular walls. In addition to nitroglycerin, 2 major
                                    metabolites, 1,2- and 1,3-dinitroglycerin are found in plasma.
                                    The mean elimination half-life of both 1,2- and
                                    1,3-dinitroglycerin is about 40 minutes. The 1,2- and
                                    1,3-dinitroglycerin metabolites have been reported to possess
                                    some pharmacological activity, whereas the glycerol mononitrate
                                    metabolites of nitroglycerin are essentially inactive. Higher
                                    plasma concentrations of the dinitro metabolites, with their
                                    nearly 8-fold longer elimination half-lives, may contribute
                                    significantly to the duration of pharmacologic effect.</p>
<p>In the above referenced pharmacokinetic study the average
                                    initial half-lives (T<span class="Sub">½α</span>) of
                                    nitroglycerin, and its 1,2- and 1,3-dinitroglycerin metabolites
                                    were estimated to be 3, 10, and 11 minutes, respectively. The
                                    half-life of disappearance of the nitroglycerin
                                        (T<span class="Sub">½β</span>) (5 minutes) was
                                    significantly less than the half-life of appearance
                                        (T<span class="Sub">½α</span>) of the 1,2- and
                                    1,3-dinitroglycerin metabolites suggesting the possibility of an
                                    additional compartment into which the nitroglycerin disappears
                                    from plasma prior to being metabolized into the dinitroglycerin
                                    metabolites. A second indication of this other compartment is
                                    that the appearance of nitroglycerin metabolites in plasma was
                                    delayed in some subjects, with zero plasma levels seen for
                                    4-6 minutes after dosing. In some subjects,
                                    nitroglycerin metabolites appeared only after nitroglycerin
                                        C<span class="Sub">max</span> had been observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="B8CEC19D-C060-44D7-BCD1-78060D708A8C"></a><a name="section-13"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="B24DBD76-BC7A-43DD-95C9-262CA5F8BC52"></a><a name="section-13.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal carcinogenicity studies with sublingually
                                    administered or lingual spray nitroglycerin have not been
                                    performed.</p>
<p>Rats receiving up to 434 mg/kg/day of dietary
                                    nitroglycerin for 2 years developed dose-related fibrotic and
                                    neoplastic changes in liver, including carcinomas, and
                                    interstitial cell tumors in testes. At the highest dose, the
                                    incidences of hepatocellular carcinomas was 52% compared
                                    to 0% in untreated controls. Incidences of testicular
                                    tumors were 52% vs. 8% in controls. Lifetime
                                    dietary administration of up to 1058 mg/k/day of nitroglycerin
                                    was not tumorigenic in mice.</p>
<p>Nitroglycerin was found to have reverse mutation activity
                                    in the <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span>
                                        typhimurium</span></span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA1535 (Ames assay). A similar mutation in<span class="Italics"><span class="Emphasis">S. typhimurium</span></span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> was also reported for other NO donors.
                                    Nevertheless, there was no evidence of mutagenicity in an<span class="Italics"><span class="Emphasis">in vivo</span></span> dominant lethal assay with male rats treated with
                                    oral doses of up to about 363 mg/kg/day or in <span class="Italics"><span class="Emphasis">ex vitro cytogenic</span></span> tests in rat and dog tissues. <span class="Italics"><span class="Emphasis">In vitro</span></span> cytogenetic assay using Chinese hamster ovary cells
                                    showed no chromosomal aberrations.</p>
<p>In a 3-generation reproduction study, rats received
                                    dietary nitroglycerin at doses up to about 408 mg/kg/day (males)                               to 452 mg/kg/day (females) for 5 months (females) or 6 months
                                    (males) prior to mating of the F<span class="Sub">0 </span>generation with
                                    treatment continuing through successive F<span class="Sub">1</span> and
                                        F<span class="Sub">2</span> generations. The highest dose was associated
                                    with decreased feed intake and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> in both sexes at
                                    all matings. No specific effect on the fertility of the
                                    F<span class="Sub">0</span> generation was seen. <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">Infertility</span> noted in
                                    subsequent generations, however, was attributed to increased
                                    interstitial cell tissue and aspermatogenesis in the high-dose
                                    males.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="EC25B3B6-372E-4987-B940-C687E428C384"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">In a randomized, double-blind, single-center,
                            single-administration, placebo-controlled, 4-period cross-over study in
                            30 subjects with <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">stable angina pectoris</span>, statistically significant
                            dose-related increases in exercise tolerance were seen following doses
                            of 200, 400, and 800 mcg of nitroglycerin delivered by NitroMist
                            compared to placebo.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="BB20DA97-79C1-4EF7-9758-B0FEC0563E1B"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Each box of NitroMist contains one glass bottle coated with
                            red/orange transparent plastic which assists in containing the glass and
                            medication should the bottle be shattered. Each unit contains 8.5 g (Net
                            Content) of nitroglycerin lingual aerosol and will deliver 230 metered
                            sprays containing 400 mcg of nitroglycerin per actuation.</p>
<p>NDC-0812-0032-35</p>
<ul>
<li>Storage<p class="First">Store at room temperature (25°C,
                                    77°F); excursions permitted to 15-30°C (59 -
                                    85°F) </p>
<br>
</li>
<li>Handling<p class="First">NitroMist contains a highly flammable
                                    propellant (butane). Do not forcefully open a NitroMist bottle,
                                    do not have the container burned after use, and do not spray
                                    directly toward flames.</p>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="E59189C4-95BA-4A69-9CDC-E887E8C2E421"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="AD8C4BAE-C6AF-4D73-A189-41E4D8934E91"></a><a name="section-16.1"></a><p></p>
<h2>17.1 Interaction with PDE5 inhibitors</h2>
<p class="First">NitroMist should not be used in patients who are using
                                    medications for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> such as sildenafil,
                                    vardenafil, and tadalafil. These products have been shown to
                                    increase the hypotensive effects of nitrate drug such as
                                    NitroMist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="A450049D-0DF0-4207-B5FF-274FC913DE6F"></a><a name="section-16.2"></a><p></p>
<h2>17.2 Administration</h2>
<p class="First">NitroMist is meant to be sprayed on or under the tongue
                                    at the beginning of angina or to prevent an <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina attack</span>.
                                    Treatment with nitroglycerin products such as NitroMist may be
                                    associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> on standing, especially just
                                    after rising from a laying or seated position. This effect may
                                    be more frequent in patients who have consumed alcohol, since
                                    alcohol use contributes to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. If possible, patients
                                    should be seated when taking NitroMist. This reduces the
                                    likelihood of <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> due to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>
                                        [<span class="Italics"><span class="Emphasis">see <span class="Bold"><span class="Emphasis"><a href="#CDAE66DA-88D7-4F93-838F-05ACB6C4905C">DOSAGE AND ADMINISTRATION 2.3</a></span></span>]</span></span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="E3CA8EC0-9FB3-4E93-82DF-E7DA303DF477"></a><a name="section-16.3"></a><p></p>
<h2>17.3 <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headaches</span> can sometimes accompany treatment with
                                    nitroglycerin. In patients who get these <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, the
                                    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> may indicate activity of the drug. Tolerance to
                                    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span> develops.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="AC055682-EE41-4613-AABD-6A551224A6A7"></a><a name="section-16.4"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span>, <span class="product-label-link" type="condition" conceptid="4080559" conceptname="Baboon syndrome">drug rash</span> and <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> have been
                                    reported in patients receiving nitrate therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="F4332BEC-9E08-4BCA-969B-8F0502A3D0C2"></a><a name="section-16.5"></a><p></p>
<h2>17.5 Container information</h2>
<p class="First">The NitroMist bottle should not be forcefully opened.
                                    Because NitroMist contains a highly flammable propellant
                                    (butane), do not have the container burned after use and do not
                                    spray directly towards flames.</p>
<p>While the container is in the upright position, if the
                                    liquid reaches the top to middle of the hole on the side of the
                                    container, a new supply should be obtained. When the liquid
                                    reaches the bottom of the hole, the remaining doses will have
                                    less than label content.</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NITROMIST 		
					</strong><br><span class="contentTableReg">nitroglycerin aerosol, spray</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0812-0032</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TRANSMUCOSAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>NITROGLYCERIN</strong> (nitroglycerin) </td>
<td class="formItem"></td>
<td class="formItem">400 ug</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>caprylic/capric diglycerol succinate</strong></td>
<td class="formItem">10400 ug  in 1 </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>peppermint oil</strong></td>
<td class="formItem">200 ug  in 1 </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>L(‑)‑menthol</strong></td>
<td class="formItem">11 ug  in 1 </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>n-butane</strong></td>
<td class="formItem">22000 ug  in 1 </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0812-0032-35</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">230  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>NovaDel Pharma Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2007<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>B7D658B8-0161-20FC-4911-4893205581FB</div>
<div>Set id: F9EB07A2-5EBC-40EA-9890-1A0B03E859FF</div>
<div>Version: 1</div>
<div>Effective Time: 20070330</div>
</div>
</div> <div class="DistributorName">NovaDel Pharma Inc.</div></p>
</body></html>
